Targeted therapy for the post-operative conjunctiva: SPARC silencing reduces collagen deposition.
CONCLUSIONS: SPARC targeted therapy effectively reduced both SPARC and collagen production in the operated mouse conjunctiva. This proof-of-concept study suggests that targeted treatment of fibrosis in glaucoma surgery is safe and feasible, with the potential to extend to a range of potential genes associated with fibrosis.
PMID: 30021812 [PubMed - as supplied by publisher]
Source: The British Journal of Ophthalmology - Category: Opthalmology Authors: Seet LF, Tan YF, Toh LZ, Chu SW, Lee YS, Venkatraman SS, Wong TT Tags: Br J Ophthalmol Source Type: research
More News: Eyes | Genetics | Glaucoma | Nanotechnology | Opthalmology | Pathology | Study | UK Health